Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co 688505.SS · CNY
Health Care · Shanghai · 🇨🇳 China
7.03
-0.71%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co
Its shares trade on Shanghai under the ticker 688505.SS. It has been listed since 13 August 2002. In the fiscal year to 31 December 2025, it reported revenue of CN¥685.8m and a net loss of CN¥157.4m. At that date it held total assets of CN¥2.39bn and shareholders' equity of CN¥2.12bn.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2002-08-13. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The firm's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The firm conducts its businesses in the domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 13 Aug 2002
- Employees
- 605
- Website
- fd-zj.com ↗
Leadership
Pay as last reported
- Ms. Yan XueChief Financial Officer, Secretary of the Board, Director, since 2010CN¥2.2m
- Ms. Xiaowen LiGeneral Manager
- Mr. Dajun ZhaoDeputy General Manager, Executive Director, since 2002CN¥2.5m
- Mr. Yu ChenDeputy General Manager
- Jun LiDeputy General ManagerCN¥2.4m
- Ms. Daiqing YuDeputy General Manager
- Mr. Bo ShenNon-Executive Director
- Ms. Xiaoyang YuNon-Executive Director
- Mr. Siu Wing LamIndependent Non-Executive Director
- Mr. Hongguang WangIndependent Non-Executive Director
- Mr. Peilong XuIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- One of the key strengths of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is its strong research and development capabilities. The company has a team of highly skilled scientists and researchers who are dedicated to discovering and developing innovative pharmaceutical products.
- Another strength is the company's strategic location in Zhangjiang High-Tech Park, which provides access to a thriving biopharmaceutical industry ecosystem. This enables collaborations and knowledge exchange with other industry players, fostering innovation and growth.
Weaknesses
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd faces certain weaknesses, such as a limited product portfolio. The company may be heavily reliant on a few key products, which increases the risk associated with product sales and revenue generation.
- Another weakness is the company's dependency on external funding sources for its research and development activities. This can pose financial challenges and potential delays in product development if funding sources are not secured or if there is a disruption in funding.
Opportunities
- One significant opportunity for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd lies in the growing global demand for innovative biopharmaceutical products. The company can leverage its research capabilities to develop new drugs that address unmet medical needs in various therapeutic areas.
- Additionally, partnerships and collaborations with academic institutions, research organizations, and other pharmaceutical companies can provide access to complementary technologies, expertise, and resources, enhancing the company's competitive advantage.
Threats
- The biopharmaceutical industry is highly competitive, and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd faces threats from both domestic and international competitors. The company needs to continuously innovate and protect its intellectual property rights to stay ahead in the market.
- Regulatory challenges and stringent approval processes for new drugs can also pose threats. Delays or failures in obtaining necessary approvals from regulatory authorities can impact the company's ability to bring new products to market in a timely manner.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.